公开(公告)号：US20250144148A1

公开(公告)日：2025-05-08

申请号：US18834375

申请日：2023-01-26

Applicant: ROHTO PHARMACEUTICAL CO., LTD. ,  SONIKURE HOLDINGS LIMITED

Inventor： Hikari KUROGI ,  Smriti ARYA ,  Ka Ming CHOI ,  Hau Yi Paulisally LO ,  Wai Leung Langston SUEN ,  Wai Ki LAU ,  Jamison Thomas ARMSTRONG

IPC: A61K35/28 ,  C12N5/0775 ,  C12N13/00

Abstract: An object of the present invention is to provide a method for obtaining cells having a high migration ability or cells having a high proliferation ability as cells having an increased therapeutic effect on diseases. The present invention is a method for preparing cells for treating diseases, a method for promoting a migration ability of cells, and a method for promoting a proliferative ability of cells, each of the methods comprising subjecting cells to ultrasonic treatment. The frequency of the ultrasonic treatment is preferably 30 kilohertz to 2.0 megahertz, and the cells are preferably mesenchymal stem cells. In addition, the present invention also includes cells obtained by the preparation method of the present invention.

公开(公告)号：US12226436B2

公开(公告)日：2025-02-18

申请号：US16071123

申请日：2017-01-18

Applicant: ROHTO PHARMACEUTICAL CO., LTD

Inventor： Daisuke Kajita ,  Satsuki Fukushima ,  Shigeru Miyagawa ,  Yoshiki Sawa

IPC: A61K35/28 ,  A61K35/35 ,  A61K35/51 ,  A61K35/545

Abstract: It has been found that a cell cluster obtained by causing just isolated cells to adhere to each other secretes adiponectin after transplantation to the heart, and thereby has an excellent therapeutic effect on heart disease.

公开(公告)号：US20240390416A1

公开(公告)日：2024-11-28

申请号：US18695745

申请日：2022-09-30

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Takuto MORIKAWA ,  Sachiko MATSUMOTO ,  Rie MATSUKI

IPC: A61K33/30 ,  A61K9/00 ,  A61K31/79 ,  A61P27/04

Abstract: The present invention relates to an ophthalmological composition containing zinc chloride (A) and a polyvinyl-based polymer compound (B).

公开(公告)号：US12090133B2

公开(公告)日：2024-09-17

申请号：US17498147

申请日：2021-10-11

Applicant: The Mentholatum Company ,  ROHTO Pharmaceutical Co., Ltd.

Inventor： Yoshiaki Kawaguchi ,  Tammam Alama

IPC: A61K31/325 ,  A61K9/00 ,  A61K9/06

CPC classification number: A61K31/325 ,  A61K9/0014 ,  A61K9/06

Abstract: Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.

公开(公告)号：US20240033311A1

公开(公告)日：2024-02-01

申请号：US18483161

申请日：2023-10-09

Applicant: TSUBOTA LABORATORY, INC. ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Kazuo TSUBOTA ,  Toshihide KURIHARA

IPC: A61K36/16 ,  A61P27/10 ,  A61K9/00 ,  A61K31/05 ,  A61K31/202

CPC classification number: A61K36/16 ,  A61P27/10 ,  A61K9/0056 ,  A61K31/05 ,  A61K31/202

Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.

公开(公告)号：US11357798B2

公开(公告)日：2022-06-14

申请号：US15749766

申请日：2016-08-03

Applicant: OSAKA UNIVERSITY ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Kohji Nishida ,  Ryuuhei Hayashi ,  Yoichi Honma ,  Toru Okubo ,  Shun Shibata

IPC: A61K35/28 ,  A61P27/02 ,  C12N5/0775 ,  C12N5/00 ,  C12Q1/02 ,  A61K35/12

Abstract: The present invention relates to mesenchymal stem cell-derived microparticles having activity that promotes the growth of corneal epithelial stem cells and/or corneal epithelial cells, activity that maintains corneal epithelial stem cells in an undifferentiated state or promotes the formation of colonies thereby, and function that protects corneal epithelium.

公开(公告)号：US11331390B2

公开(公告)日：2022-05-17

申请号：US16094919

申请日：2017-04-21

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Yasuko Matsumura

IPC: A61K47/26 ,  A61K9/00 ,  A61K31/045 ,  A61K31/14 ,  A61K31/355 ,  A61K47/44 ,  A61K47/10 ,  C08J5/00 ,  A61K47/18 ,  A61K47/12 ,  A61K47/02 ,  A61K47/22

Abstract: The first aspect of the present invention relates to an ophthalmic composition comprising (A) one or more kinds selected from the group consisting of terpenoid, a tocopherol, and a benzyl ammonium compound and a salt thereof, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin.
The second aspect of the present invention relates to an ophthalmic composition comprising (A2) a surface active component and (B2) a buffer, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin.

公开(公告)号：US11273437B2

公开(公告)日：2022-03-15

申请号：US15764731

申请日：2016-10-19

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Tetsuo Koike ,  Masahiro Takimoto ,  Yoshiki Yagi

IPC: B01L1/02 ,  B25J21/02 ,  C12M3/00 ,  B25J21/00 ,  C12M1/00 ,  C12M1/12

Abstract: Provided is a cell treatment apparatus that includes: an isolator; a disposal box that includes a storage part; and a decontamination unit, wherein the disposal box includes: a first opening and closing device that is configured to allow the isolator and the storage part to be communicated with each other at the time of disposal of the waste product and allow them to be shut off from each other after the putting-in of the waste product and before the disposal of the same; and a second opening and closing device that is configured to allow the storage part and the outside to be communicated with each other at the time of disposal of the waste product, which has been put into the storage part, and allow them to be shut off from each other after the disposal of the waste product.

公开(公告)号：US11103464B2

公开(公告)日：2021-08-31

申请号：US15038897

申请日：2014-11-28

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Satoshi Yamaguchi ,  Kazuhiro Tsuji

IPC: A61K31/01 ,  A61K31/355 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/44 ,  A61K9/00 ,  A61K9/08 ,  A61K36/18 ,  A61K9/12 ,  A61K9/107

Abstract: The present invention relates to an aqueous composition for ophthalmological use or otolaryngological use, the aqueous composition containing: (A) a petrolatum; and two or more (B) nonionic surfactants.

公开(公告)号：US20200171112A1

公开(公告)日：2020-06-04

申请号：US16614176

申请日：2018-05-15

Applicant: TSUBOTA LABORATORY, INC. ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Kazuo TSUBOTA ,  Toshihide KURIHARA

IPC: A61K36/16 ,  A61K31/202 ,  A61K31/05 ,  A61K9/00 ,  A61P27/10

Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.